CollPlant Biotechnologies Ltd.
| NASDAQ: CLGN | Healthcare / Biotechnology / Israel |
| 14.50 | 0 | 0.00 | Vol 5.89K | 1Y Perf 27.66% |
| Apr 23rd, 2021 10:53 DELAYED |
| BID | 14.21 | ASK | 14.50 | ||
| Open | 14.51 | Previous Close | 14.49 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 23.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 58.62 | Finscreener Ranking | ★★ 46.60 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | + 38.17 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★ 44.37 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 82.22M | Earnings Rating | Strong Buy | |
| Price Range Ratio 52W % | 46.55 | Earnings Date | 26th May 2021 |
Today's Price Range 14.4714.51 | 52W Range 6.0024.26 | 5 Year PE Ratio Range -2.50-2.50 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.35% | ||
| 1 Month | 18.27% | ||
| 3 Months | -0.62% | ||
| 6 Months | 107.74% | ||
| 1 Year | 27.66% | ||
| 3 Years | 159.86% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -216.56 | |||
ROE last 12 Months | -129.35 | |||
ROA (5Y Avg) | -69.45 | |||
ROA last 12 Months | -51.22 | |||
ROC (5Y Avg) | -158.97 | |||
ROC last 12 Months | -96.81 | |||
Return on invested Capital Q | -32.45 | |||
Return on invested Capital Y | -74.68 | |||
Assets Turnover | 0.50 | |||
Receivables Turnover | 9.10 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -16.40 | ||||
| 31.69 | ||||
| 25.99 | ||||
| - | ||||
| -61.70 | ||||
| -0.65 | ||||
| 31.69 | ||||
| 0.45 | ||||
| 134.28M | ||||
| Forward PE | 10.17 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.30 | ||||
| 1.70 | ||||
| 0.40 | ||||
| 0.76 | ||||
| -131.00 | ||||
| Leverage Ratio | 2.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 51.10 | ||||
| -143.60 | ||||
| -132.60 | ||||
| -2 291.40 | ||||
| -73.23 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.53M | ||||
| 0.56 | ||||
| 114.75 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.30 | -0.42 | -40.00 |
| Q03 2020 | 0.92 | 0.07 | -92.39 |
| Q02 2020 | -0.25 | -0.20 | 20.00 |
| Q01 2020 | -0.50 | -0.26 | 48.00 |
| Q04 2019 | -0.13 | -0.88 | -576.92 |
| Q03 2019 | -0.26 | -0.41 | -57.69 |
| Q02 2019 | -0.41 | -0.37 | 9.76 |
| Q01 2019 | -0.41 | -0.27 | 34.15 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | 0.50 | 292.31 | Positive |
| 6/2021 QR | -0.06 | -200.00 | Negative |
| 12/2021 FY | 1.01 | 274.07 | Positive |
| 12/2022 FY | 1.42 | 4.41 | Positive |
| Next Report Date | 26th May 2021 |
| Estimated EPS Next Report | 0.50 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 5.89K |
| Shares Outstanding | 5.67M |
| Trades Count | 29 |
| Dollar Volume | 9.35M |
| Avg. Volume | 114.61K |
| Avg. Weekly Volume | 36.13K |
| Avg. Monthly Volume | 42.21K |
| Avg. Quarterly Volume | 131.82K |
CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) stock closed at 14.5 per share at the end of the most recent trading day (a -0.07% change compared to the prior day closing price) with a volume of 16.46K shares and market capitalization of 82.22M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 38 people. CollPlant Biotechnologies Ltd. CEO is Yehiel Tal.
The one-year performance of CollPlant Biotechnologies Ltd. stock is 27.66%, while year-to-date (YTD) performance is 34.63%. CLGN stock has a five-year performance of %. Its 52-week range is between 6 and 24.26, which gives CLGN stock a 52-week price range ratio of 46.55%
CollPlant Biotechnologies Ltd. currently has a PE ratio of -16.40, a price-to-book (PB) ratio of 31.69, a price-to-sale (PS) ratio of 25.99, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -51.22%, a ROC of -96.81% and a ROE of -129.35%. The company’s profit margin is -73.23%, its EBITDA margin is -132.60%, and its revenue ttm is $5.53 Million , which makes it $0.56 revenue per share.
Of the last four earnings reports from CollPlant Biotechnologies Ltd., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.50 for the next earnings report. CollPlant Biotechnologies Ltd.’s next earnings report date is 26th May 2021.
The consensus rating of Wall Street analysts for CollPlant Biotechnologies Ltd. is Strong Buy (1), with a target price of $23, which is +58.62% compared to the current price. The earnings rating for CollPlant Biotechnologies Ltd. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CollPlant Biotechnologies Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CollPlant Biotechnologies Ltd. has a Buy technical analysis rating based on Technical Indicators (ADX : 25.16, ATR14 : 1.29, CCI20 : 80.96, Chaikin Money Flow : 0.35, MACD : -0.49, Money Flow Index : 48.77, ROC : 4.32, RSI : 44.23, STOCH (14,3) : 87.91, STOCH RSI : 0.98, UO : 72.63, Williams %R : -12.09), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CollPlant Biotechnologies Ltd. in the last 12-months were:
CollPlant Biotechnologies Ltd.
CollPlant Biotechnologies Ltd is a regenerative medicine company. It is focused on developing and commercializing tissue repair products, initially for 3D-bio printing of tissues and organs, dermal fillers for aesthetics, orthobiologics, and advanced wound care markets. Its products are based on recombinant human collagen produced from genetically-modified tobacco plants, and the company focuses on orthopedics and advanced wound care.
CEO: Yehiel Tal
Telephone: +972 732325600
Address: 4 Oppenheimer Street, Rehovot 7670104, , IL
Number of employees: 38
